Search Results - "Dusilková, Nina"

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial by Stopka, Tomáš, Minařík, Lubomír, Dusilková, Nina, Pešta, Michal, Kulvait, Vojtěch, Špaček, Martin, Zemanová, Zuzana, Kalousová, Marta, Jonášová, Anna

“…Trial registration GA trial is registered under EudraCT#: 2013-001639-38…”
Get full text

Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways by Minařík, Lubomír, Pimková, Kristýna, Kokavec, Juraj, Schaffartziková, Adéla, Vellieux, Fréderic, Kulvait, Vojtěch, Daumová, Lenka, Dusilková, Nina, Jonášová, Anna, Vargová, Karina Savvulidi, Králová Viziová, Petra, Sedláček, Radislav, Zemanová, Zuzana, Stopka, Tomáš

“…The mechanisms by which myelodysplastic syndrome (MDS) cells resist the effects of hypomethylating agents (HMA) are currently the subject of intensive…”
Get full text

Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas by Dusílková, Nina, Bašová, Petra, Polívka, Jindřich, Kodet, Ondřej, Kulvait, Vojtěch, Pešta, Michal, Trněný, Marek, Stopka, Tomáš

“…Primary cutaneous T-cell lymphomas (CTCL) affect the skin and tend to transform and spread. CTCL involves primarily the Mycosis fungoides (MF) and more…”
Get full text

Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum by Sochor, Marek, Basova, Petra, Pesta, Michal, Dusilkova, Nina, Bartos, Jiri, Burda, Pavel, Pospisil, Vit, Stopka, Tomas

“…MicroRNAs (miRs) represent a distinct class of posttranscriptional modulators of gene expression with remarkable stability in sera. Several miRs are oncogenic…”
Get full text

Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas by Huskova, Hana, Korecka, Katarina, Karban, Josef, Vargova, Jarmila, Vargova, Karina, Dusilkova, Nina, Trneny, Marek, Stopka, Tomas

“…The transcription factor PU.1 and its inhibitory microRNA-155 (miR-155) are important regulators of B-cell differentiation. PU.1 downregulation coupled with…”
Get full text

Randomized Open-Labeled Academic Trial Comparing Standard AZA Therapy with Combination of G-CSF with AZA in High Risk MDS Patients - Interim Analysis by Jonasova, Anna, Minarik, Lubomir, Kulvait, Vojtech, Pesta, Michal, Schaffartzikova, Adel, Kislik, Galina, Dusilkova, Nina, Zemanova, Zuzana, Stopka, Tomas

“…Introduction: Myelodysplastic syndrome (MDS) is characterized by differentiation blockade, cytopenias with commontransfusion dependency and immune defects…”
Get full text

Clonal Architecture of MDS Somatic Mutations Dynamically Changes during Azacitidine Therapy and Has Very Limited Potential to Predict Patient Outcome by Polgarova, Kamila, Kulvait, Vojtech, Vargova, Karina, Minarik, Lubomir, Dusilkova, Nina, Zemanova, Zuzana, Jonasova, Anna, Stopka, Tomas

“…Introduction: Myelodysplastic syndromes (MDS) are clonal disorders of myeloid hematopoietic stem cells. Recent studies has shown that nearly 90% of patients…”
Get full text

Somatic mutation dynamics in MDS patients treated with azacitidine indicate clonal selection in patients-responders by Polgarova, Kamila, Vargova, Karina, Kulvait, Vojtech, Dusilkova, Nina, Minarik, Lubomir, Zemanova, Zuzana, Pesta, Michal, Jonasova, Anna, Stopka, Tomas

“…Azacitidine (AZA) for higher risk MDS patients is a standard therapy with limited durability. To monitor mutation dynamics during AZA therapy we utilized…”
Get full text

Tracking the Somatic Mutations in Azacitidine-Treated MDS Patients Documents Clonal Development and AZA Responsiveness by Stopka, Tomas, Vargova, Karina, Kulvait, Vojtech, Vargova, Jarmila, Dusilkova, Nina, Jonasova, Anna

“…Introduction and hypothesis: Somatic gene mutations develop in ~78% Myelodysplastic syndrome (MDS) patients. MDS progresses into an unstable phase…”
Get full text

Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Is a New Biomarker for Mantle Cell Lymphoma: Expression, Localization, and Phosphorylation Study by Stopka, Tomas, Vargova, Jarmila, Vargova, Karina, Dusilkova, Nina, Kulvait, Vojtech, Pospisil, Vit, Zavadil, Jiri, Trneny, Marek, Klener, Pavel

“…Mantle cell lymphoma (MCL) is a relatively distinct B-cell non-Hodgkin lymphoma subtype with aggressive and often recurrent clinical course. At diagnosis, MCL…”
Get full text

Somatic Mutation-Detecting Algorithm Enables Analysis of MDS Patients during Azacitidine Therapy by Stopka, Tomas, Vargova, Karin, Kulvait, Vojtech, Dusilkova, Nina, Jonasova, Anna T.

“…Introduction: Somatic mutation detection in myelodysplastic syndrome (MDS) is very important in deciphering clonal pathogenesis of every patient and if…”
Get full text

Erythroid Transcription Factor GATA-1 Binds and Represses PU.1 Gene – Candidate Mechanism Of Epigenetic Repression Of PU.1 and Inefficient Erythropoiesis In MDS by Burda, Pavel, Curik, Nikola, Dusilkova, Nina, Papadopoulos, Giorgio L, Strouboulis, John, Jonasova, Anna T, Stopka, Tomas

“…Myelodysplastic syndrome (MDS) is often manifested by anemia due to ineffective erythropoiesis. Upon transformation to MDS/AML the uniform population of…”
Get full text